Actively Recruiting
Phase 1b Study of Belzutifan Effects on CAIX Tumor Expression Using 89Zr-DFO-girentuximab PET in Adults with Advanced Clear Cell Renal Cell Carcinoma
Led by NYU Langone Health · Updated on 2026-07-30
12
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the effects of belzutifan on Carbonic Anhydrase IX CAIX expression in patients with metastatic clear cell renal cell carcinoma RCC. The study aims to observe changes in CAIX expression caused by inhibiting hypoxia-inducible factor 2 alpha HIF-2 using belzutifan. This is the first time such changes will be evaluated using imaging, and findings may help develop future combination therapies involving belzutifan and CAIX-targeted agents like radioimmunotherapy. Participants will receive belzutifan orally at a dose of 120 mg daily for 28 days. They will undergo imaging with 89Zr-DFO-girentuximab PET scans before starting treatment and again 28 days after beginning belzutifan. The PET imaging uses a single slow intravenous dose of 10 mg of 89Zr-DFO-girentuximab to assess CAIX expression in tumors. During the study, participants will be monitored for changes in PET scan uptake values comparing baseline and four weeks after treatment starts. Researchers will also track any severe toxicities occurring by the fourth week. The total study participation includes the treatment period and imaging assessments to evaluate how belzutifan affects tumor CAIX expression and patient safety.
CONDITIONS
Brief Title
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
Research Team
C
Cancer Trials (NYU Langone Health Perlmutter Cancer Center)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
